ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

RICHARD KHALIL M.D.

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

22,770Medicare Part D Prescriptions Filled, Including Refills

Rank: 14 out of 2680

$2.3M Total Retail Price of All Prescriptions

Rank: 2 out of 2680

704 Patients Receiving at Least One Drug in Part D
61%Patients 65 Years and Older
96% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 704 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

15% of this provider’s 704 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Risky Drugs to Seniors

1% of this provider’s 14,485 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

50% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$101 was the average price of a prescription from this provider, compared to $67 among peers.

Prescriptions per Patient

32 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
SIMVASTATIN 831 592 1 1
FUROSEMIDE 656 459 2 7
AMLODIPINE BESYLATE 565 404 3 3
CRESTOR 543 358 4 15
WARFARIN SODIUM 473 351 5 12
NEXIUM 443 253 6 19
ZOLPIDEM TARTRATE 370 183 7 17
SPIRIVA 354 217 8 36
METOPROLOL TARTRATE 338 277 9 8
PROAIR HFA 331 177 10 52
LISINOPRIL 306 258 11 5
NAMENDA 288 255 12 43
TRAMADOL HCL 277 177 13 33
TAMSULOSIN HCL 267 204 14 25
LEVOTHYROXINE SODIUM 262 217 15 4
ZETIA 246 195 16 69
HYDROCODONE-ACETAMINOPHEN 244 84 S3 17 13
AZOR 240 168 18 188
UNIFINE PENTIPS 238 106 10 19 266
DIOVAN 227 146 20 26
OMEPRAZOLE 220 167 21 2
ONGLYZA 220 143 21 179
METFORMIN HCL 210 127 23 6
RANEXA 207 122 24 173
WELCHOL 203 111 25 222
POTASSIUM CHLORIDE 197 143 26 29
BYSTOLIC 196 127 27 104
LOVAZA 194 109 28 47
MIRTAZAPINE 190 151 29 48
ATORVASTATIN CALCIUM 189 126 30 10
VENTOLIN HFA 188 41 31 61
PANTOPRAZOLE SODIUM 172 69 32 44
CLOPIDOGREL 170 98 33 30
EXFORGE 169 143 34 139
JANUVIA 158 121 35 34
QVAR 154 50 36 331
LOSARTAN POTASSIUM 150 71 37 18
SINGULAIR 149 63 38 64
EXELON 147 135 39 162
NAPROXEN 145 87 40 91
PLAVIX 143 121 41 41
AMMONIUM LACTATE 143 110 41 118
DIGOXIN 141 97 43 59
GABAPENTIN 137 47 44 21
POLYETHYLENE GLYCOL 3350 137 109 44 55
QUETIAPINE FUMARATE 122 109 46 72
CARVEDILOL 120 67 47 27
ALENDRONATE SODIUM 120 110 47 20
SYMBICORT 120 66 47 114
LEVEMIR FLEXPEN 118 53 50 170
SINGLE USE SWAB 117 50 51 196
AZITHROMYCIN 116 63 52 40
HYDROCORTISONE 113 87 53 208
VICTOZA 2-PAK 113 26 53 458
CYMBALTA 111 51 55 56
CLONIDINE HCL 110 71 56 84
TRIBENZOR 110 66 56 247
JANUMET 110 59 56 83
EFFIENT 109 80 59 371
BENICAR 109 84 59 122
METOPROLOL SUCCINATE 109 96 59 11
MEGESTROL ACETATE 107 89 R 62 296
CYCLOBENZAPRINE HCL 105 21 R 63 95
LANTUS SOLOSTAR 104 46 64 68
FLUTICASONE PROPIONATE 103 39 65 38
LYRICA 100 43 66 107
DESOXIMETASONE 99 67 67 401
TRADJENTA 98 69 68 374
LEVETIRACETAM 94 69 69 94
MONTELUKAST SODIUM 93 29 70 134
OLANZAPINE 91 64 71 128
PATADAY 89 58 72 261
LACTULOSE 89 48 72 100
ADVAIR DISKUS 89 63 72 32
ENDOCET 84 24 S2 75 180
HYDROCHLOROTHIAZIDE 82 54 76 9
AMITIZA 81 49 77 190
COREG CR 80 60 78 292
SERTRALINE HCL 79 56 79 23
ALBUTEROL SULFATE 77 47 80 97
HUMALOG 75 50 81 246
CITALOPRAM HBR 74 56 82 22
PRANDIN 74 66 82 191
VESICARE 74 43 82 214
LANTUS 73 52 85 70
ENALAPRIL MALEATE 73 40 85 24
SILENOR 72 25 10 87 495
OXYBUTYNIN CHLORIDE ER 72 50 87 135
RANITIDINE HCL 71 56 89 35
NOVOLOG FLEXPEN 71 19 89 194
LUNESTA 70 37 91 297
METOCLOPRAMIDE HCL 70 45 91 150
DONEPEZIL HCL 69 61 93 28
DIVALPROEX SODIUM 69 44 93 90
PAROXETINE HCL 69 37 93 62
RISPERIDONE 69 64 93 67
DALIRESP 68 23 97 352
FAMOTIDINE 67 36 98 65
LIDODERM 67 44 98 74
SPIRONOLACTONE 66 59 100 86
TIZANIDINE HCL 65 24 101 282
BYETTA 62 29 102 428
MECLIZINE HCL 61 37 103 105
KOMBIGLYZE XR 61 61 103 293
HALOPERIDOL 60 31 105 153
CICLOPIROX 60 47 105 248
CIPROFLOXACIN HCL 60 46 105 85
CARBIDOPA-LEVODOPA 60 46 105 88
TRIAMCINOLONE ACETONIDE 58 24 109 138
ENABLEX 58 52 109 401
LEVEMIR 58 37 109 224
TRAZODONE HCL 56 34 112 60
DIOVAN HCT 56 36 112 54
SEROQUEL XR 56 20 112 454
FINASTERIDE 56 36 112 80
RAPAFLO 54 30 116 449
PHENYTOIN SODIUM EXTENDED 54 29 116 207
AMOX TR-POTASSIUM CLAVULANATE 54 30 116 145
PREDNISONE 54 25 116 45
LEVOFLOXACIN 53 35 120 108
FLUOXETINE HCL 52 29 121 76
HUMALOG MIX 75-25 52 35 121 347
NAPRELAN 51 25 10 123 557
PRADAXA 50 41 124 203
PRAVASTATIN SODIUM 50 47 124 16
NUEDEXTA 50 28 124 444
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 1, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.